Speaker Lecture Titles

Speaker Lecture Titles

Partial List of confirmed speakers below:


Last NameFirst Name CountryAbstract Title
AsheKaren
USA
TBA
AttemsJohannes
UK
THE ROLE OF PYROGLUATMYLATED AMYLOID- Β IN THE PATHOGENESIS AND DIAGNOSIS OF ALZHEIMER'S DISEASE
BezprozvannyIlyaUSACALCIUM SIGNALING AND SYNAPTIC LOSS IN ALZHEIMER'S DISEASE
BlennowKaj SwedenTHE EXPANDED AD FLUID BIOMARKER TOOLBOX - PERFORMANCE FOR DIAGNOSTICS, THERAPY MONITORING AND SCREENING
BrooksDavidUKIMAGING THE TEMPORAL AND SPATIAL  INTER-RELATIONSHIPS OF PATHOLOGY WITH PET IN ESTABLISHED AND PRODROMAL ALZHEIMER'S AND PARKINSON'S DISEASE
BrundinPatrikUSANOVEL THERAPEUTIC TARGETS FOR PARKINSON'S DISEASE
BuGoujun USACENTRAL AND PERIPHERAL APOE IN COGNITION AND ALZHEIMER'S DISEASE
BueeLuc FranceIMPROVING TAU IMMUNOTHERAPY BY ENGINEERING NEW TOOLS: FROM IGGS TO VHHS
CheclerFrédéric FranceFUNCTIONAL PRESENILINS-PINK1 INTERPLAY
Chiba-FalekOrnitUSATHE TALE OF SNCA IN SYNUCLEINOPATHIES: AN INTERPLAY OF GENE DEREGULATION, AGING, AND THE NUCLEUS
ClevelandDonUSAGENE SILENCING THERAPY IN AD AND PD
CudkowicsMeritUSAACCELERATING THERAPY DEVELOPMENT: LESSONS FROM NEURONEXT PHASE II NETWORK AND AMYOTROPHIC LATERAL SCLEROSIS
​Cuello
Claudio​​Canada

POTENTIAL TRANSLATIONAL VALUE OF EXPERIMENTAL THERAPEUTICS IN AD TRANSGENIC MODELS

De StrooperBart BelgiumTHE VARIOUS CELLULAR RESPONSES IN ALZHEIMER'S DISEASE
DiamondMarc USABIOCHEMISTRY AND STRUCTURAL BIOLOGY OF TAU PRIONS: IMPACT ON DIAGNOSIS AND THERAPY
FrenkelDan IsraelTARGETING PATHOLOGICAL PATHWAYS IN GLIA IN AD:  WHEN FRIENDS BECOME FOES
FrisoniGiovanni B.SwitzerlandTHE GUT MICROBIOTA IN AD: PRECLINICAL AND CLINICAL EVIDENCE OF AN ASSOCIATION
FutermanAnthonyIsraelLYSOSOMAL STORAGE DISEASES AND PD
GalvinJamesUSACAN DEMENTIA BE PREVENTED: LESSONS LEARNED AND APPLIED IN RESEARCH AND CLINICAL PRACTICE
Geula ChangizUSATBA
GiladiNirIsraelPERSONALIZED APPROACH TO TREATING PATIENTS WITH PARKINSON, THE ROLE OF GENETIC BACKGROUND
GoateAlisonUSABIOLOGICAL PATHWAYS IMPLICATED IN ALZHEIMER'S DISEASE RISK THROUGH GENETIC STUDIES
GoldeTodd USAA PRECLINICAL  ROAD MAP TO DEVELOP COMBINATORIAL THERAPIES THAT CAN RESCUE BRIAN ORGAN FAILURE IN NEURODEGENERATIVE DISEASE
GrowdonJohnUSAMOLECULAR PET SCANS REVEAL THE BASIS OF DEMENTIA IN PARKINSON DISEASE
HenekaMichaelGermanyTBA
HiguchiMakatoJapanIN-VIVO IMAGING OF TAU AND ALPHA-SYNUCLEIN PATHOLOGIES FROM MICROSCOPIC TO MACROSCOPIC SCALES
HoltzmanDavidUSAROLE OF APOE IN NEURODEGENERATION
HortJakubCzech  RepublicIMPACT OF AMYLOID PET ON DIAGNOSIS AND THERAPY IN CLINICAL SETTING
HymanBradleyUSATBA
InestrosaNibaldo C.ChileWNT SIGNALING HAS A KEY ROLE IN ALZHEIMER´S DISEASE: REGULATION OF APP PROCESSING AND TAU PHOSPHORYLATION
IsacsonOleUSALIPID AND PROTEIN INTERACTIONS CAUSING NEURODEGENERATIVE DISEASES
IwatsuboTakeshiJapanTOWARD DISEASE-MODIFYING THERAPY FOR ALZHEIMER'S DISEASE: JAPANESE ADNI AND A4 STUDIES
JeonBeom.SKoreaPERIPHERAL TISSUE BIOMARKER OF PARKINSON'S DISEASE
KooEdward USATBA
KorczynAmos D.IsraelTHE NEGLECTED AVENUES IN PREVENTING AD
Kulisevsky
​Jaime
​Spain

​HALLUCINATIONS IN PD: NEUROANATOMICAL CORRELATES

LaferlaFrankUSATBA
LazarovOrly USAMOLECULAR MECHANISM OF NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE
LeeVirginiaUSATBA
LeeSeung-JaeKoreaMECHANISM OF ALPHA-SYNUCLEIN AGGREGATE PROPAGATION
LehericyStephaneFranceTBA
LemereCynthiaUSAFOCUSED ULTRASOUND IMPROVES THERAPEUTIC EFFICACY OF ANTI-PYROGLU3 ABETA IMMUNOTHERAPY IN APP/PS1 MICE
LiptonStuartUSATBA
MarekKenUSAHOW CAN BIOMARKERS IN PARKINSON DISEASE INFORM CLINICAL TRIALS – THE PPMI STUDY
MastersColinAustraliaPROGRESS TOWARDS PRIMARY PREVENTION OF AD THROUGH DETECTION OF PERSONS AT RISK
MichaelsonDaniel M. IsraelCOMPLIMENTARY APPROACHES TO ALZHEIMER  THERAPY  BASED ON REVERSAL OF THE HYPOLIPIDATION OF APOE4 AND  ON  ANTI-APOE4 IMMUNOTHERAPY
MirelmanAnat IsraelMOTOR –COGNITIVE INTERACTIONS IN NEURODEGENERATION
Mook-JungInheeKoreaTBA
MorganDaveUSAMARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE
Morizane AsukaJapanSTEM CELL THERAPY FOR PARKINSON'S DISESE PROGRESSING TO THE CLINIC
MorrisJohn MUSARACIAL SIMILARITIES AND DIFFERENCES IN ALZHEIMER BIOMARKERS
MuckeLennart USAPROTEINOPATHIES OF THE AGING BRAIN: FROM NETWORK DYSFUNCTION TO NEURODEGENERATION
MulthaupGerhardCanadaMOLECULAR DISSECTION OF AMYLOID CLEARANCE PATHWAYS: TOXIC VERSUS NON-TOXIC ABETA
NordbergAgneta SwedenTHE COMPLEXIITY OF TAU PET IMAGING IN EARLY DIAGNOSIS OF NEURODEGENERATIVE PROTEINOPATHIES
OuteiroTiagoGermanyTHE EFFECT OF ALPHA-SYNUCLEIN ON TRANSCRIPTION: INSIGHTS INTO SYNUCLEINOPATHIES
PetersenRonaldUSAPROGRESS TOWARD EVALUATING THE NIA-AA ALZHEIMER'S FRAMEWORK
PoeweWernerAustriaDISEASE-MODIFYING THERAPIES FOR PD: WHERE DO WE STAND ?
PolymenidouMagdalini SwitzerlandPATHOLOGICAL TDP-43 ASSEMBLIES AND DISEASE HETEROGENEITY
PradoMarcoCanadaCHOLINERGIC CONTROL OF PATHOLOGY AND COGNITION IN ALZHEIMER'S DISEASE
Ranum LauraUSAREPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION IN C9ORF72 ALS/FTD: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES
RascolOliverFranceNOVEL THERAPIES FOR PARKINSON DISEASE
RektorovaIrenaCzech RepublicCOMBINING IMAGING AND CLINICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LEWY BODY DISEASES
SchapiraAntonyUKNOVEL THERAPEUTIC STRATEGIES FOR DISEASE MODIFICATION IN PARKINSON DISEASE'
ScheltensPhilip The NetherlandsTAKING ALZHEIMER DIAGNOSIS TO THE NEXT LEVEL
SchlossmacherMichaelCanadaANTI-MICROBIAL EFFECTS OF SNCA AND LRRK2 INFORM CLINICAL TRIALS IN PARKINSON'S
SchmidtReinhold Austria

MRI-DETECTED IRON DEPOSITION IN NORMAL AGING AND DEMENTIA

SchmitzTaylorUKTBA
SchwartzMichal IsraelHARNESSING THE SYSTEMIC AND THE BRAIN'S SPECIFIC IMMUNE SYSTEM TO COMBAT ALZHEIMER'S DISEASE
SegalMenahemIsraelCALCIUM STORES AND ALZHEIMER'S DISEASE
SelkoeDennis J.USANEW CONCEPTS ABOUT THE BIOLOGY OF ALPHA-SYNUCLEIN IN VIVO
ShenJie USAPRESENILINS AND FAMILIAL ALZHEIMER'S DISEASE
SmallDavid H.AustraliaAPP EXPRESSION CONTROLS THE SPATIAL-TEMPORAL PATTERN OF NEURODEGENERATION IN ALZHEIMER'S DISEASE
SnyderPeterUSANON-AMYLOID RETINAL BIOMARKERS FOR PRECLINICAL AD SCREENING
SoininenHilkkaFinlandTBA
SolomonBeka IsraelTBA
SoreqHermonaIsraelCIRCULAR RNAS CONTROL OXIDATIVE STRESS RESPONSES IN THE PARKINSON BRAIN
SperlingReisaUSATHE NEXT GENERATION OF ALZHEIMER'S DISEASE PREVENTION TRIALS  
SpillantiniMaria GraziaUKTBA
St. George-HyslopPeterCanadaMICROGLIAL SIGNALLING PATHWAYS INVOLVING TREM2, PLCG2, ABI3 AND CD33 IN MICROGLIAL DYSFUNCTION IN AD
SudhofTomUSATHE CELL BIOLOGY OF SYNAPSE FORMATION AND SYNAPSE DEGENERATION
TanziRudolph E.USAALZHEIMER'S DISEASE: AN AUTO-INNATE IMMUNE DISORDER?
TrojanowskiJohn Q. USATBA
TsaiLi-Huei USAGAMMA ENTRAINMENT USING SENSORY STIMULATION (GENUS) PROVIDES NEUROPROTECTION AND ENHANCES COGNITIVE FUNCTION 
Van BroeckhovenChristine BelgiumTBA
VassarRobertUSA
BACE1: THE BETA-SECRETASE ENZYME IN HEALTH AND ALZHEIMER'S DISEASE
WeinerMichaelUSAMEASURING BRAIN, CEREBROSPINAL FLUID, AND BLOOD FOR AMYLOID AND TAU TO DIAGNOSE ALZHEIMER'S DISEASE; LESSONS FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INTITIATIVE
WeinerHoward USAROLE OF MICROGLIA IN ALZHEIMER'S DISEASE 
WilcockDonnaUSATHERAPEUTIC TARGETING OF TREM2 FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WongPhilip USATARGETING TDP-43, A GUARDIAN OF THE TRANSCRIPTOME, FOR NEURODEGENERATIVE DISEASE
WszolekZbigniewUSAPERRY SYNDROME – PARKINSONIAN  CONDITION WITH TDP-43 PATHOLOGY
XuHuaxiUSATREM2 MEDIATES MICROGLIAL FUNCTION IN RESPONSE TO BETA-AMYOID
YueZhenyuUSATBA
ZetterbergHenrik SwedenDISEASE PROGRESSION IN ALZHEIMER'S AND PARKINSON'S DISEASES - WHAT HAPPENS TO THE FLUID BIOMARKERS?  
ZhouJiaweiChinaBALANCING THE INNATE IMMUNE SYSTEM IN THE BRAIN: INTERPLAY BETWEEN NG2 GLIAL AND MICROGLIAL CELLS
ZlokovicBerislavUSAALZHEIMER'S DISEASE: A MATTER OF BLOOD-BRAIN BARRIER DYSFUNCTION?